Precision NanoSystems Announces New Cell Therapy Reagent for Lipid Nanoparticle -based mRNA Delivery to T Cells

Vancouver, Bc (ots/PRNewswire) - Precision NanoSystems (PNI) , a global leader
in innovative solutions for genetic medicine development, today launched the
GenVoy-ILM(TM) T Cell Kit for mRNA to enable lipid nanoparticle (LNP)-based ex
vivo gene transfer. Scientists can now use mRNA-LNP to efficiently and
reproducibly generate high yields of engineered primary human T cells using a
simple workflow.

The GenVoy-ILM T Cell Kit for mRNA uses LNP designed to exploit endogenous
uptake pathways to efficiently deliver mRNA into activated human primary T cells
to mediate titratable, uniform protein expression levels with high cell
viability. The mRNA-LNP are also compatible with established T cell culture
media allowing rapid integration into existing workflows. The combination of
non-disruptive mRNA delivery technology and seamless integration with cell
culture protocols eliminates cell recovery times post-treatment to accelerate
the production of T cell therapies.

"The COVID-19 mRNA-LNP vaccines have demonstrated the power of lipid
nanoparticle technology for the rapid development of highly effective genetic
medicines" said Dr. James Taylor, CEO & cofounder of PNI. "PNI believes that LNP
technology can also accelerate the development of transformative cell therapies
and we are thrilled to launch a LNP reagent kit specifically designed for the
efficient delivery of mRNA into T cells using PNI's proprietary GenVoy-ILM(TM)
delivery platform."

Dr. Angelo Cardoso, Director of the Laboratory for Cellular Medicine at the
Beckman Research Institute at City of Hope, also expressed excitement about
PNI's launch of GenVoy-ILM T Cell Kit for mRNA, "LNP designed for defined cell
types open new opportunities for the manufacture of gene-edited cell therapies
and, hopefully in the future, in vivo gene targeting."

Learn more about the GenVoy-ILM T Cell Kit for mRNA by registering for our
upcoming webinars on May 6th and May 11th. And Join us at the American Society
of Gene & Cell Therapy Annual Meeting for a PNI sponsored symposium
"Accelerating Genetic Medicine Development with Lipid Nanoparticles" at 2-3:30
PM ET on May 13th, 2021.

Learn more about those events at https://www.precisionnanosystems.com/resources-
and-community/learningpaths/events (https://c212.net/c/link/?t=0&l=en&o=3134336-
1&h=3303698213&u=https%3A%2F%2Fwww.precisionnanosystems.com%2Fresources-and-comm
unity%2Flearningpaths%2Fevents&a=%C2%A0https%3A%2F%2Fwww.precisionnanosystems.co
m%2Fresources-and-community%2Flearningpaths%2Fevents) .

Learn more about Precision NanoSystems and the GenVoy-ILM T Cell Kit for mRNA at
https://www.precisionnanosystems.com (https://c212.net/c/link/?t=0&l=en&o=313433
6-1&h=3144902315&u=https%3A%2F%2Fwww.precisionnanosystems.com%2F&a=https%3A%2F%2
Fwww.precisionnanosystems.com) .

About Precision NanoSystems Inc. (PNI)

PNI is a global leader ushering in the next wave of genetic medicines in
infectious diseases, cancer and rare diseases. We work with the world's leading
drug researchers to understand disease and create the therapeutics and vaccines
that will define the future of medicine. PNI offers proprietary technology
platforms and comprehensive expertise to enable researchers to translate disease
biology insights into non-viral genetic medicines.

Helena Rebec, Precision NanoSystems, Email: [e-mail], Phone:
1-888-618-0031 Ext. 222

Additional content: http://presseportal.de/pm/155024/4894477
OTS: Precision Nanosystems